BRCA突变卵巢癌患者的乳腺癌发病率:纵向观察研究
该多中心回顾性队列纳入502例2000–2018年确诊卵巢癌的BRCA1/2突变携带者,分析乳腺癌发生情况。卵巢癌后乳腺癌发生率低(6.2%),无乳腺癌相关死亡,卵巢癌后乳腺癌与仅卵巢癌患者的总生存无统计学差异,提示常规乳腺监测而非降低风险手术可能足够。
要点
- BRCA1/2突变卵巢癌患者卵巢癌后乳腺癌发生率低(6.2%)。
- 无乳腺癌相关死亡记录。
- 卵巢癌后乳腺癌与仅卵巢癌患者总生存无统计学差异。
核心结论
- BRCA1/2突变卵巢癌患者卵巢癌后乳腺癌发生率低,常规乳腺监测而非降低风险手术可能足够。
研究设计与样本
- 多中心回顾性纵向观察研究,纳入502例2000–2018年在以色列7个医疗中心和纽约1个中心确诊卵巢癌的BRCA1/2突变携带者。
主要发现
- 卵巢癌诊断中位年龄55.8岁(范围23.9–90.1)。
- 31.5%有乳腺癌家族史,17.1%有卵巢癌家族史。
- 67.3%为德系犹太人,72.9%为BRCA1携带者。
- 17.5%乳腺癌先于卵巢癌,6.2%乳腺癌在卵巢癌后诊断,2.2%同时发生。
- 卵巢癌后乳腺癌诊断中位时间46.0个月(范围11–168);同时患乳腺癌和卵巢癌者(n=31)中83.9%为BRCA1、16.1%为BRCA2突变;无乳腺癌相关死亡;卵巢癌后乳腺癌与仅卵巢癌患者总生存无统计学差异。
临床怎么用
- 对BRCA1/2突变卵巢癌生存者,常规乳腺监测可能足够,而非必须行降低风险手术。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated the incidence of breast cancer and overall survival in a multi-center cohort of ovarian cancer patients carrying BRCA1/2 mutations in order to assess risks and formulate optimal preventive interventions and/or surveillance. METHODS: Medical records of 502 BRCA1/2 mutation carriers diagnosed with ovarian cancer between 2000 and 2018 at 7 medical centers in Israel and one in New York were retrospectively analyzed for breast cancer diagnosis. Data included demographics, type of BRCA mutations, surveillance methods, timing of breast cancer diagnosis, and family history of cancer. RESULTS: The median age at diagnosis of ovarian cancer was 55.8 years (range, 23.9-90.1). A third (31.5%) had a family history of breast cancer and 17.1% of ovarian cancer. Most patients (67.3%) were Ashkenazi Jews, 72.9% were BRCA1 carriers. Breast cancer preceded ovarian cancer in 17.5% and was diagnosed after ovarian cancer in 6.2%; an additional 2.2% had a synchronous presentation. Median time to breast cancer diagnosis after ovarian cancer was 46.0 months (range, 11-168). Of those diagnosed with both breast cancer and ovarian cancer (n = 31), 83.9% and 16.1% harbored BRCA1 and BRCA2 mutations, respectively. No deaths from breast cancer were recorded. Overall survival did not differ statistically between patients with an ovarian cancer diagnosis only and those diagnosed with breast cancer after ovarian cancer. CONCLUSION: The low incidence of breast cancer after ovarian cancer in women carrying BRCA1/2 mutations suggests that routine breast surveillance, rather than risk-reducing surgical interventions, may be sufficient in ovarian cancer survivors.
引用
- Safra T, Waissengrin B, Gerber D, et al. Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study. Gynecol Oncol. 2021. PMID: 34172288. doi:10.1016/j.ygyno.2021.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。